Cencora, Inc. (COR)
(Delayed Data from NYSE)
$224.81 USD
+2.25 (1.01%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $224.79 -0.02 (-0.01%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Company Summary
Chesterbrook, PA-based Cencora is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes.
The company reports through two segments – Pharmaceutical Distribution and Other. The Pharmaceutical Distribution business includes the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG). The segment services healthcare providers in the pharmaceutical supply channel. The ABSG division provides pharmaceutical distribution and other services mainly to physicians, who specialize in a variety of diseases, especially oncology, and to other ...
Company Summary
Chesterbrook, PA-based Cencora is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes.
The company reports through two segments – Pharmaceutical Distribution and Other. The Pharmaceutical Distribution business includes the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG). The segment services healthcare providers in the pharmaceutical supply channel. The ABSG division provides pharmaceutical distribution and other services mainly to physicians, who specialize in a variety of diseases, especially oncology, and to other health care providers, including dialysis clinics. The ABDC division is involved in the distribution of branded pharma drugs and generic drugs, over-the-counter healthcare products, home healthcare supplies and equipment and related services to a range of healthcare providers.
The “Other” segment consists of AmerisourceBergen Consulting Services (ABCS), World Courier and MWI Veterinary Supply. The ABCS business provides commercialization support services to pharmaceutical and biotech manufacturers.
It is worth mentioning that Cencora made a strategic evaluation of its reporting structure in order to represent its expanded international presence because of the 2021 buyout of Alliance Healthcare. Consequently, starting from fiscal 2022, the company has realigned its reporting structure under two reportable segments — U.S. Healthcare Solutions and International Healthcare Solutions.
Cencora was formely known as AmerisourceBergen. AmerisourceBergen changed its name and ticker symbol to Cencora and COR, respectively, effective Aug 30.
FY23 at a Glance
Total revenue in fiscal 2023 came in at $262.17 billion. The U.S. Healthcare Solutions contributed to 89.8% of net revenues in fiscal 2023. The International Healthcare Solutions segment accounted for 10.2% of net revenues.
General Information
Cencora, Inc
1 West First Avenue
Conshohocken, PA 19428
Phone: 610-727-7000
Fax: 800-640-5221
Email: investorrelations@cencora.com
Industry | Medical Services |
Sector | Medical |
Fiscal Year End | September |
Last Reported Quarter | 9/30/2024 |
Earnings Date | 11/6/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 3.21 |
Current Year EPS Consensus Estimate | 13.62 |
Estimated Long-Term EPS Growth Rate | 10.60 |
Earnings Date | 11/6/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 222.56 |
52 Week High | 247.66 |
52 Week Low | 182.75 |
Beta | 0.44 |
20 Day Moving Average | 1,811,895.75 |
Target Price Consensus | 261.43 |
4 Week | -7.22 |
12 Week | -0.47 |
YTD | 8.36 |
4 Week | -10.24 |
12 Week | -5.77 |
YTD | -11.11 |
Shares Outstanding (millions) | 197.05 |
Market Capitalization (millions) | 43,854.74 |
Short Ratio | NA |
Last Split Date | 6/16/2009 |
Dividend Yield | 0.92% |
Annual Dividend | $2.04 |
Payout Ratio | 0.15 |
Change in Payout Ratio | -0.03 |
Last Dividend Payout / Amount | 8/9/2024 / $0.51 |
Fundamental Ratios
P/E (F1) | 15.01 |
Trailing 12 Months | 16.76 |
PEG Ratio | 1.41 |
vs. Previous Year | 14.38% |
vs. Previous Quarter | -12.11% |
vs. Previous Year | 10.90% |
vs. Previous Quarter | 8.52% |
Price/Book | 41.35 |
Price/Cash Flow | 13.02 |
Price / Sales | 0.15 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 266.60 |
3/31/24 | 268.67 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 4.15 |
3/31/24 | 4.13 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.89 |
3/31/24 | 0.89 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.55 |
3/31/24 | 0.53 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.94 |
3/31/24 | 0.94 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.65 |
3/31/24 | 0.67 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 0.82 |
3/31/24 | 0.83 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 5.38 |
3/31/24 | 6.15 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 15.22 |
3/31/24 | 15.13 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 3.93 |
3/31/24 | 3.41 |
9/30/24 | Pending Next EPS Report |
6/30/24 | 79.71 |
3/31/24 | 77.31 |